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Background.— Heart rate is a key determinant of both myocardial ischaemia and prognosis in
patients with coronary disease. Reducing heart rate is known to relieve ischaemia and improve
cardiovascular prognosis. Currently there is no information about heart rate distribution and
predictors of high heart rate in patients with stable coronary artery disease (CAD).
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MOTS CLÉS
Coronariens stables ;
Fréquence cardiaque
haut risque. Étant donné le rôle thérapeutique et pronostique majeur de la fréquence cardiaque
de repos chez les coronariens, nos données soulignent la nécessité de prendre en compte la
fréquence cardiaque chez ces patients à haut risque.
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ackground
eart rate is a predictor of major cardiovascular events in
oth the general population and in patients with various
ardiovascular diseases [1-3]. Since the publication of the
ramingham cohort data, resting heart rate has emerged
s a strong predictor of mortality in hypertensive sub-
ects [4,5]. The association between resting heart rate and
ardiovascular mortality has also been observed in more
han 22 000 patients with essential hypertension requiring
rug therapy and with documented stable coronary artery
g
t
is droits réservés.
isease (CAD) aged 50 years or older from the multina-
ional randomized International Verapamil-SR/Trandolapril
tudy (INVEST) trial [6]. In this clinical setting, there
as a clear relationship between both baseline and on-
reatment heart rate and long-term outcomes. Moreover,
he INVEST trial raised the importance of comorbidities
ssociated with elevated heart rate, and the results sug-L. Lorgis et al.
Methods.— The L’Hypertendu Coronarien Vu En Médecine Générale (LHYCORNE) cohort was a
prospective observational study involving consecutive stable CAD patients with treated hyper-
tension. Patients with atrial ﬁbrillation were excluded from the analysis. Heart rate distribution
and factors independently associated with heart rate above that of the cohort mean were
analysed.
Results.— The study population comprised 8922 stable CAD patients in sinus rhythm (76% were
men; mean age 66± 11 years; mean systolic/diastolic blood pressures 141/82mmHg; 26% had
diabetes). The mean resting heart rate was 70± 6 bpm; the distribution was: 7% for <60 bpm,
38% for 60—69, 38% for 70—79 bpm, 14% for 80—89 bpm, and 2% for > 90 bpm. The mean rest-
ing heart rate of the patients on beta-blockers (62% of the population) was 69± 8 bpm versus
73± 8 bpm in subjects not on beta-blockers (p < 0.001). Eight independent predictors of heart
rate≥ 70 bpm were identiﬁed.
Conclusion.— Data from this large cohort demonstrate that few patients meet recommenda-
tions to lower heart rate to <60 bpm. Over 50% of stable CAD patients had a heart rate≥ 70 bpm,
presenting a particularly high-risk proﬁle. Given the therapeutic and prognostic role of resting
heart rate in CAD patients, our ﬁndings emphasize the need to consider heart rate in these
high-risk patients.
© 2009 Elsevier Masson SAS. All rights reserved.
Résumé
Introduction.— La fréquence cardiaque est un déterminant majeur de l’ischémie myocardique
et inﬂuence le pronostic des patients coronariens. On sait que la réduction de la fréquence
cardiaque peut soulager l’ischémie et améliorer le pronostic cardiovasculaire. Cependant, il
n’existe pas à ce jour, de données sur la fréquence cardiaque des patients coronariens, ni sur
les facteurs prédictifs d’une fréquence cardiaque élevée.
Méthodes.— La cohorte l’hypertendu coronarien vu en médecine générale (LHYCORNE) est une
étude prospective observationnelle ayant inclus des patients coronariens stables consécutifs,
traités pour une hypertension. Les patients présentant une ﬁbrillation auriculaire ont été exclus
de l’analyse. Nous avons analysé la fréquence cardiaque, ainsi que les facteurs associés de fac¸on
indépendante à une fréquence cardiaque plus élevée que la moyenne.
Résultats.— La population de l’étude était composée de 8922 patients coronariens stables
en rythme sinusal (76 % d’hommes ; âge moyen : 66± 11 ans ; pression artérielle sys-
tolique/diastolique moyenne 141/82mmHg ; 26% de diabétiques). La fréquence cardiaque
moyenne de repos était de 70± 6 bpm, avec la distribution suivante : 7 % inférieure à 60 bpm,
38% entre 60 et 69 bpm, 38% entre 70 et 79 bpm, 14% entre 80 et 89 bpm et 2% supérieure à
90 bpm. Pour les patients sous bétabloquants (62 % de la population), la fréquence cardiaque de
repos se situait à 69± 8 bpm contre 73± 8 bpm chez les sujets sans bétabloquants (p < 0,001).
Nous avons identiﬁé huit facteurs prédictifs indépendants d’une fréquence cardiaque supérieure
à 70 bpm.
Conclusion.— Les résultats de cette vaste population démontrent que peu de patients adhèrent
aux recommandations visant une fréquence cardiaque inférieure à 60 bpm. Plus de 50% des
coronariens stables présentent une fréquence cardiaque supérieure à 70 bpm, avec un proﬁl àested that gender may inﬂuence the heart rate response to
reatment.
The morbidity-mortality evaluation of the If inhibitor
vabradine in patients with coronary disease and left
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ventricular dysfunction (BEAUTIFUL) study recently showed
that in CAD patients with left ventricular dysfunction,
an elevated heart rate (≥ 70 bpm) was associated with a
signiﬁcantly higher risk of cardiovascular death, hospital-
ization for heart failure, revascularization and myocardial
infarction [7]. In this study more than 50% of patients had a
heart rate ≥70 bpm, despite receiving beta-blocker therapy.
In such a population, exclusive heart rate reduction with
ivabradine resulted in a signiﬁcant 36% reduction in fatal
and non-fatal myocardial infarction, and a 30% reduction
in coronary revascularization [8]. The results from the
Coronary Artery Surgery Study (CASS) registry, a large
multinational registry of CAD patients undergoing coronary
angiography in the 1970s, also suggested that in routine
clinical practice, the majority of patients had a heart rate
> 70 bpm [9].
Overall, the conclusions of these studies converge to
indicate that heart rate is a strong prognostic factor in car-
diovascular disease, and highlight the need to evaluate heart
rate in CAD patients. However, there is little information
regarding the distribution and determinants of resting heart
rate in CAD patients in routine clinical practice.
Using data from a large, French, contemporary cohort of
stable CAD patients with treated hypertension, we aimed to
investigate the distribution of resting heart rate and factors
associated with an elevated heart rate.
Methods
Patients
The l’Hypertendu Coronarien Vu en Médecine Générale
(LHYCORNE) study was a prospective, French observa-
tional study of consecutive adults (≥ 18 years) with stable
CAD and treated hypertension, who attended a consulta-
tion with their general practitioner (GP) between January
and December 2004. Women who were pregnant or
breast-feeding were excluded from the study. CAD was
deﬁned as documented previous myocardial infarction,
percutaneous or surgical coronary revascularization, or
angiographic evidence of≥ 50% stenosis in a major coronary
artery.
Data collection
In January 2004, 4000 randomly selected GPs were invited to
participate in the LHYCORNE study. To obtain a representa-
tive sample of subjects with CAD, each GP randomly invited
one to six individuals who complied with the inclusion crite-
ria to participate. The GPs completed patient record forms,
which recorded the following information: patients’ clini-
cal characteristics, risk factors, medical history, results of
clinical examination, blood pressure and heart rate mea-
surements, lifestyle data, treatments and laboratory test
results. Data-collection rules were identical for all GPs.
Physical activity was assessed for work and leisure times.
Subjects were classiﬁed into two categories based on their
levels of physical activity:
• physically inactive (no or occasional physical activity) or;
• physically active (regular and intense physical activity
lasting >20minutes at least once per week).
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aemodynamic parameters
atients were considered hypertensive if diagnosed as such
y their GP, if receiving antihypertensive drugs or if their
lood pressures were ≥140mmHg systolic and/or ≥90mmHg
iastolic. Blood pressure was measured according to current
uidelines [10]. Resting heart rate was determined by mea-
urement of the radial pulse during a one-minute recording
fter a ﬁve-minute rest in a supine position. Angina was
eﬁned as typical chest pain (located over the sternum or
n both the left side of the chest and arm), which starts on
xertion and causes the person to stop or slow down and
isappears within 10minutes.
The survey was performed in accordance with the Decla-
ation of Helsinki and was consistent with the International
onference on Harmonisation of Good Clinical Practice
uidelines. The survey was observational and its method-
logy did not interfere with the doctors’ normal practices
r with their relationship with their patients.
tatistical methods
ontinuous variables are expressed as means± standard
eviations (SD) and categorical variables as percentages.
omparison of proportions between groups of patients was
erformed by the 2 test. As recent data suggest a strong
rognostic role of heart rate ≥70 bpm [7], heart rate was
ichotomized at 70 bpm for greater clinical relevance. Back-
ard logistic regression analysis was used to determine
actors associated with a high heart rate (≥70 bpm). Only the
ariables that were univariately associated with an elevated
eart rate (p < 0.05) were entered into the multivariable
nalysis. Results are expressed as odds-ratios (OR) with 95%
onﬁdence intervals (CI). A p value< 0.05 was considered
o be signiﬁcant. Statistical analyses were conducted using
AS® software (SAS Institute Inc, Cary, NC) by an indepen-
ent statistical centre (Taylor Nelson Sofres, Montrouge,
rance) that exclusively held the database.
esults
etween January and December 2004, 3373 of 4000
84.3%) GPs, representing 7% of those registered in France
www.ameli.fr), enrolled up to three consecutive stable
AD patients into the study. A total of 9921 patients were
creened by the GPs, of whom 875 were excluded because
f the presence of atrial ﬁbrillation. A further 124 patients
ere excluded because their resting heart rates were not
ocumented. The baseline characteristics of these patients,
ncluding age, sex, diastolic blood pressures (DBP), systolic
lood pressure (SBP), and proportion with angina, were sim-
lar to those of the study population (data not shown).
verall, 8922 patients were included in the present anal-
sis. Most of the study patients (97%) were followed up by a
ardiologist.The characteristics of the study population are shown
n Table 1. Over three-quarter of the patients were male,
lmost one-quarter were obese or diabetic, 46% had a
rior myocardial infarction, 61% had a prior coronary revas-
ularization and 46% suffered from angina. The majority
544 L. Lorgis et al.
Table 1 Characteristics of the study population.
Stable CAD
patients
(n = 8922)
Demographic
Age, years 66± 11
Men 76
Presenting characteristics and risk factors
Systolic blood pressure, mmHg 141± 14
Diastolic blood pressure, mmHg 82± 9
Obesity (BMI ≥30 kg/m2) 21
Uncontrolled hypertension 59
Resting heart rate, bpm 70± 6
Resting heart rate ≥70 bpm 54
Smoker 16
Diabetes 26
Dyslipidaemia 68
Prior myocardial infarction 46
Prior coronary revascularization 61
Percutaneous coronary intervention 44
Coronary artery bypass graft surgery 17
Clinical symptoms of angina 46
Clinical symptoms of heart failure 14
No or occasional physical activity 52
Chronic treatments
Beta-blocker 62
Angiotensin converting enzyme inhibitor 74
Calcium channel blocker 34
Statin 73
Antiplatelet 86
Diuretic 28
Other antianginal drug 56
Nitrate 19
Trimetazidine 14
Molsidomine 14
Nicorandil 13
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BMI: body mass index; CAD: coronary artery disease.
59%) of patients had uncontrolled hypertension (SBP ≥140
nd/or DBP ≥90mmHg). The mean resting heart rate
as 70± 6 bpm, with a median of 72 (interquartile range
4—77) bpm. The distribution of heart rates is shown in
ig. 1. Most patients (54%) had a resting heart rate ≥70 bpm.
ixty-two percent of patients were on beta-blockers and had
mean resting heart rate of 69± 8 bpm versus 73± 8 bpm for
hose not on beta-blockers (p < 0.001).
Patients with a heart rate ≥70 bpm (n = 4883, 55%) were
haracterized by a lower proportion of men, and a higher
ate of smokers and diabetics compared to patients with a
eart rate <70 bpm (n = 4039) (Table 2). Patients with an ele-
ated heart rate were also more likely to suffer from angina,
ince 50% of the patients with a resting heart rate ≥70 bpm
xperienced clinical signs of angina and less frequently
nderwent coronary revascularization (Table 2). Moreover,
hese patients were less likely to be on beta-blockers and to
e physically active. An elevated heart rate (≥70 bpm) was
eported in 46% of the patients on beta-blocker therapy.
s
t
2
s
wigure 1. Distribution of heart rate in stable coronary artery dis-
ase (CAD) patients.
ndependent predictors of beta-blocker
herapy and of elevated heart rate
n a backward logistic regression analyses including the vari-
bles in Table 1, prior myocardial infarction (OR 1.48, 95%
I 1.34—1.64), obesity (OR 1.23, 95% CI 1.09—1.38), revas-
ularization (OR 1.94, 95% CI 1.74—2.15), dyslipidaemia (OR
.16, 95% CI 1.04—1.29) and physical activity (OR 1.12, 95%
I 1.01—1.23) were independently associated with the use
f beta-blockers.
By multivariable analysis, eight factors were indepen-
ently associated with an elevated heart rate (Fig. 2).
bsence of beta-blocker therapy was the most powerful fac-
or associated with a high resting heart rate (p < 0.0001). The
ogistic equation of the model was tested for its discrimina-
ive power, yielding a c-statistic of 0.66 (p < 0.01).
iscussion
eart rate is a modiﬁable risk factor for cardiovascular dis-
ase. A recent randomized trial and a meta-analysis have
uggested that lowering heart rate has a beneﬁcial impact
n cardiovascular events, even in high-risk patients, and in
ddition to those procured by a high level of evidence-based
herapy [8,11]. There are, however, few data regarding the
istribution of heart rate in high-risk patients. Our ﬁndings
rom this large cohort of stable CAD patients monitored in
outine clinical practice by GPs, and in most cases by car-
iologists, show that only a few patients have a heart rate
60 bpm, as recommended in current guidelines [12]. Addi-
ionally, more than 50% of CAD patients had a heart rate
70 bpm, and such patients showed a particularly high-risk
roﬁle, in addition to their hypertension. Moreover, our ﬁnd-
ngs allowed us to identify simple prognostic factors of an
levated heart rate, such as a lack of beta-blocker therapy
nd the presence of angina.
Almost 9000 subjects were included in the present study.
he mean age was 66± 11 years, 43% were <65 and 20% were
76 years. The study population was presumed to be repre-
entative of subjects with stable angina and hypertension
reated by GPs in routine clinical practice in France in the
000s. The Polish RECENT study, which analysed a repre-
entative population of 2593 mostly hypertensive patients
ith CAD from 215GPs and 67 specialists in 2005, found a
Heart rate in stable coronary artery disease 545
Table 2 Characteristics of the study population classiﬁed according to resting heart rate.
Parameter (%) Heart rate <70 bpm (n = 4039) Heart rate ≥70 bpm (n = 4883) p
Coronary revascularization 67 56 <0.001
Male sex 77 74 <0.001
Clinical symptoms of angina 39 50 <0.001
Smoker 14 18 <0.001
Diabetes 23 27 <0.001
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Beta-blocker therapy 73
similar mean age (65± 10 years) to that in the present study,
and similar levels of cardiovascular risk factors [13]. A more
recent multicentre survey of CAD patients with hypertension
conducted by Spanish cardiologists also reported a similar
mean age (66± 10 years) to our study population [14]. In
the Euro Heart survey, which analysed data from 3779 stable
angina patients seen in 2002 by cardiologists at 197 centres
in 36 countries in Europe, most of whom were referred by a
primary care physician (71%), the mean age was even lower,
at 61± 11 [15]. Our data also show that CAD patients had a
markedly high prevalence of cardiovascular history, such as
coronary revascularization (>60%) or prior myocardial infarc-
tion (almost 50%), highlighting the disease severity of the
CAD patients seen in routine clinical practice. This preva-
lence from a contemporary cohort is much higher than that
from a large multinational randomized trial that included
2000 hypertensive patients with CAD [6]. Patients in the LHY-
CORNE study are also characterized by better, although not
optimal, control of SBP and DBP compared with that in ran-
domized trials. Our large cohort also showed that in routine
practice, more than 40% of stable CAD patients remain symp-
tomatic despite the use of anti-ischaemic treatments and
coronary revascularization.
In our study, the prevalence of atrial ﬁbrillation in the
screened population was 9% (875/9921), and these subjects
a
4
o
r
Figure 2. Independent factors associated with elevated (≥ 70 bpm) he57 <0.001
52 <0.001
ere excluded from the analysis. Only a few data are avail-
ble on the prevalence of atrial ﬁbrillation in CAD patients.
higher rate of atrial ﬁbrillation (12.5%) was found in CAD
atients from the large contemporary and geographically
iverse cohort of stable outpatients with atherothrombo-
is from the REACH Registry [16]. However, in the selected
opulation from the randomized BEAUTIFUL trial, only 27 of
238 (2.2%) screened patients had the disease. Data from
he RECENT registry reported only a 6% prevalence of atrial
brillation in CAD patients routinely treated by Polish GPs
13]. Therefore, we believe that the prevalence of atrial
brillation reported in the LHYCORNE study (9%) may be rep-
esentative of the rate seen by French GPs in routine clinical
ractice, in hypertensive patients with stable angina at the
ime of inclusion.
Our observational study showed that a high proportion
f patients with CAD treated in routine practice (54%) had
heart rate ≥70 bpm. Recent data from randomized trials
ed to the suggestion that a heart rate of 70 bpm could be
sed as a relevant threshold to stratify the risk of cardio-
ascular events in CAD patients [7], as it is associated with
34% increase in relative risk of cardiovascular death and a
6% increase in relative risk of myocardial infarction. More-
ver, in the present study, only 7% of patients had a heart
ate <60 bpm, clearly underlining the fact that the majority
art rate.
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93%) failed to meet current recommendations [12]. This
roportion is close to that found in a large multinational
andomized trial (94%) [6], but higher than in a Polish mul-
icentre trial (88%) [17].
In the present study, 62% of the patients received beta-
lockers. Importantly, in almost half of these patients, the
eart rate remained ≥70 bpm. Although the mean heart rate
f patients on beta-blockers was decreased by 4 bpm, it
emained high, at 69 bpm. These data suggest that there
s still room for improvement in the management of such
igh-risk patients by more carefully focusing on the opti-
al recommended dose of beta-blockers or by providing
lternative treatments to further lower the heart rate.
redictors of elevated heart rate
o better understand the reasons for elevated heart rate
mong these high-risk patients, we identiﬁed predictors of
levated heart rate. After adjustment for potential con-
ounders, eight variables were independently associated
ith the presence of an elevated heart rate. Of note,
ost of these variables are potentially modiﬁable, and
nclude lack of treatment (beta-blocker therapy or revas-
ularization) and lifestyle-related parameters (obesity or
ack of physical activity). Obese subjects have reduced
eart rate variability, reﬂecting autonomic imbalance, with
ncreased sympathetic activity and reduced vagal control
18].
Our ﬁndings, indicating a higher rate of cardiovascular
isk factors in patients with heart rate ≥70 bpm, are in
greement with those from the CASS registry [9], which
evealed a higher risk proﬁle in patients with the higher
uintiles of heart rate. In the present study, patients with
esting heart rate ≥70 bpm were also more likely to suffer
rom angina, independently of major risk factors, suggest-
ng that therapeutic heart rate slowing may in itself relieve
schaemia in such patients.
eneralizability of the data
hether the results from the LHYCORNE programme can be
xtrapolated to all patients with CAD is a major issue. Only
imited data are available on the characteristics of French
atients with CAD observed in routine clinical practice, but
ased on a study of the published literature, the LHYCORNE
opulation shares similar typical features to patients in most
rench registries of stable angina. The Étude Longitudinale
ans l’Angor (ELAN) study involved a cohort of more than
000 patients with known angina pectoris, recruited in 1997
y 613 cardiologists in either private or hospital practice
r both [19]. Most of the baseline characteristics of the
LAN cohort were similar to those in the LHYCORNE study,
n particular for age (mean 66 years in both) and propor-
ion of men (75% vs 76%, respectively). Moreover, a similar
ate of prior myocardial infarction or beta-blocker therapy
as found in the ELAN study compared with in LHYCORNE
47% vs 46%, and 63 vs 62%). In the ELAN cohort, hyper-
ension, as well as hypercholesterolaemia, was the most
ommon cardiovascular risk factor. In the PREVENIR III reg-
stry, data from 8288 patients in secondary prevention were
nalysed, mostly provided by GPs who were representative
f French metropolitan physicians in private practice [20].
o
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m
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ost patients were hypertensive (54%) and male (75%), and
he mean age of 66 years was similar to that in the LHY-
ORNE study, as were the baseline characteristics (diabetes,
yslipidaemia, and cardiovascular history). As mentioned
reviously, the mean age and levels of cardiovascular risk
actors and medications in the present study was similar to
hose in the Polish RECENT study [13]. Therefore, we may
elieve that most of the ﬁndings from the LHYCORNE cohort
ould be extrapolated to more generalized CAD patients.
tudy limitations
o data were available on either the beta-blocker dosage or
ompliance with treatment; therefore no conclusions can be
rawn on the link between heart rate level and beta-blocker
osage. No accurate data were available on the value of left
entricular ejection fraction or the extent of CAD on angiog-
aphy. However, in the present study, a higher rate of left
entricular dysfunction can be expected in the group with a
eart rate ≥70 bpm. Several recent studies have addressed
his issue. First, in a subgroup analysis from the BEAUTIFUL
rial, CAD patients with a heart rate ≥70 bpm had a lower
eft ventricular ejection fraction (p < 0.0001) and a higher
ate of heart failure (p < 0.0001) versus patients with a lower
eart rate [7]; second, in the 1510 patients with a myocar-
ial infarction included in the Danish Diamond study, a
igher resting heart rate correlated with worse left ventric-
lar function [21]; this concept is also indirectly supported
y the strong relation between improvements in left ventric-
lar ejection fraction and reduction in heart rate (r2 = 0.48,
< 0.0001) reported in an analysis of 35 randomized clini-
al trials in patients with chronic heart failure treated with
eart rate-lowering drugs such as beta-blockers [22]. The
HYCORNE study was initially designed primarily to investi-
ate the role of SBP control in hypertensive CAD patients.
herefore, no measure of the functional status by either
he New York Heart Association class or Canadian Cardio-
ascular Society (CCS) for angina was collected. However,
he presence or absence of symptoms as clinical signs of
ngina pectoris was carefully gathered in the overall popu-
ation by the GPs, based on the cardiologists’ data reporting.
he deﬁnition of angina used in the present study, although
ess accurate than CCS class, was based on records main-
ained by GPs and represents a validated tool for use in
eneral practice. It has also been shown to be of prog-
ostic importance, particularly in the primary care setting
23].
onclusions
esting heart rate is a simple measurement with impor-
ant prognostic implications. However, only a few patients
eet current recommendations to lower the heart rate
o <60 bpm. Moreover, more than 50% of stable coronary
atients have a heart rate ≥70 bpm, and also present a par-
icularly high-risk proﬁle. Given the strong prognostic role
f an elevated heart rate, our data emphasize the impor-
ance of measuring heart rate in stable CAD patients. As
ajor factors associated with elevated heart rate are poten-
ially modiﬁable, there may be an opportunity for improved
anagement in such high-risk patients.
[[
[
[
[
[
[
[
[
[
[
[Heart rate in stable coronary artery disease
Conﬂict of interests
LL, MZ, PJ, JPC, BV, BC and YC: no conﬂict of interest.
JB: Bayer, Sanoﬁ-Aventis, Servier.
Funding
Laboratoires Servier.
Acknowledgements
The authors are grateful for Séverine Ricard from Taylor
Nelson Sofres for the statistical analysis performed in the
database and for Philip Bastable for his help in the prepara-
tion of this manuscript.
References
[1] Palatini P. Heart rate as an independent risk factor for car-
diovascular disease: current evidence and basic mechanisms.
Drugs 2007;67(Suppl. 2):3—13.
[2] Borer JS. Heart rate: from risk marker to risk factor. Eur Heart
J 2008;10(Suppl. F):F2—6.
[3] Jouven X, Empana JP, Escolano S, et al. Relation of heart rate
at rest and long-term (> 20 years) death rate in initially healthy
middle-aged men. Am J Cardiol 2009;103:279—83.
[4] Gillman MW, Kannel WB, Belanger A, et al. Inﬂuence of heart
rate on mortality among persons with hypertension: the Fram-
ingham Study. Am Heart J 1993;125:1148—54.
[5] Thomas F, Rudnichi A, Bacri AM, et al. Cardiovascular mortality
in hypertensive men according to presence of associated risk
factors. Hypertension 2001;37:1256—61.
[6] Kolloch R, Legler UF, Champion A, et al. Impact of resting
heart rate on outcomes in hypertensive patients with coronary
artery disease: ﬁndings from the International Verapamil-
SR/Trandolapril Study (INVEST). Eur Heart J 2008;29:1327—34.
[7] Fox K, Ford I, Steg PG, et al. Heart rate as a prognostic risk fac-
tor in patients with coronary artery disease and left-ventricular
systolic dysfunction (BEAUTIFUL): a subgroup analysis of a ran-
domised controlled trial. Lancet 2008;372:817—21.
[8] Fox K, Ford I, Steg PG, et al. Ivabradine for patients
with stable coronary artery disease and left-ventricular sys-
tolic dysfunction (BEAUTIFUL): a randomised, double-blind,
placebo-controlled trial. Lancet 2008;372:807—16.[9] Diaz A, Bourassa MG, Guertin MC, et al. Long-term prognostic
value of resting heart rate in patients with suspected or proven
coronary artery disease. Eur Heart J 2005;26:967—74.
[10] Haute Autorité de santé. Prise en charge des patients adultes
atteints d’hypertension artérielle essentielle. Recommanda-
[547
tions. http://www.HAS-sante.fr 2005 (website accessed on 1st
July 2005).
11] Cucherat M. Quantitative relationship between resting heart
rate reduction and magnitude of clinical beneﬁts in post-
myocardial infarction: a meta-regression of randomized
clinical trials. Eur Heart J 2007;28:3012—9.
12] Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002
guideline update for the management of patients with chronic
stable angina–summary article: a report of the American Col-
lege of Cardiology/American Heart Association Task Force
on Practice Guidelines (Committee on the Management of
Patients With Chronic Stable Angina). Circulation 2003;107:
149—58.
13] Banasiak W, Pociupany R, Wilkins A, et al. Characteristics of
patients with coronary artery disease managed on an out-
patient basis in the population of Poland. Results of the
multicentre RECENT trial. Kardiol Pol 2007;65:132—40, discus-
sion 41-42.
14] Barrios V, Escobar C, Bertomeu V, et al. High heart rate: more
than a risk factor. Lessons from a clinical practice survey. Int J
Cardiol 2008 [Epub ahead of print].
15] Daly CA, Clemens F, Sendon JL, et al. The clinical characteris-
tics and investigations planned in patients with stable angina
presenting to cardiologists in Europe: from the Euro Heart Sur-
vey of Stable Angina. Eur Heart J 2005;26:996—1010.
16] Goto S, Bhatt DL, Rother J, et al. Prevalence, clinical proﬁle,
and cardiovascular outcomes of atrial ﬁbrillation patients with
atherothrombosis. Am Heart J 2008;156:855—63, 63 e2.
17] Banasiak W, Wilkins A, Pociupany R, et al. Pharmacotherapy
in patients with stable coronary artery disease treated on an
outpatient basis in Poland. Results of the multicentre RECENT
study. Kardiol Pol 2008;66:642—9, discussion 50.
18] Karason K, Molgaard H, Wikstrand J, et al. Heart rate vari-
ability in obesity and the effect of weight loss. Am J Cardiol
1999;83:1242—7.
19] Guize L, Ducimetiere P, Consoli SM, et al. Characteristics of a
cohort of 4,000 French patients with angina. The ELAN study.
Arch Mal Coeur Vaiss 2000;93:219—26.
20] Cambou JP, Guize L, Cantet C, et al. Prognosis at six months for
primary care patients: prognostics factors analysis. Ann Cardiol
Angeiol (Paris) 2005;54(Suppl. 1):S2—9.
21] Fosbol EL, Seibaek M, Brendorp B, et al. Long-term prognostic
importance of resting heart rate in patients with left ven-
tricular dysfunction in connection with either heart failure or
myocardial infarction: The DIAMOND study. Int J Cardiol 2008.
22] Flannery G, Gehrig-Mills R, Billah B, et al. Analysis of ran-
domized controlled trials on the effect of magnitude of heart
rate reduction on clinical outcomes in patients with systolic
chronic heart failure receiving beta-blockers. Am J Cardiol
2008;101:865—9.
23] Buckley B, Murphy AW. Do patients with angina alone have a
more benign prognosis than patients with a history of acute
myocardial infarction, revascularisation or both? Findings from
a community cohort study. Heart 2009;95:461—7.
